The incidence of melanoma is increasing worldwide, and the prognosis for patients with
high‐risk or advanced metastatic melanoma remains poor despite advances in the field …

Background Many randomised trials assessing interferon-α (IFN-α) as adjuvant therapy for
high-risk malignant melanoma have been undertaken. To better assess the role of IFN-α, an …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …

A unique collaboration of multidisciplinary experts from the European Dermatology Forum,
the European Association of Dermato-Oncology and the European Organization for …

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and
causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts …

PURPOSE: To compare the effect of pathologic sentinel lymph node (SLN) status with that of
other known prognostic factors on recurrence and survival in patients with stage I or II …

Background Based on previous meta-analyses of randomized controlled trials (RCTs), the
use of interferon alpha (IFN-α) in the adjuvant setting improves disease-free survival (DFS) …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because …

Cutaneous melanoma remains a management challenge. This year an estimated 55,000
Americans will receive a diagnosis of cutaneous melanoma, and 7900 will die from the …

PURPOSE: Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNα2b) therapy in
high-risk melanoma patients demonstrated a significant relapse-free and overall survival …